A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

Johann Sellner; Paulus Stefan Rommer

doi:10.1016/j.autrev.2018.09.012

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

Johann Sellner^* (First author)
, Paulus Stefan Rommer

^*Corresponding author for this work

Department of Neurology, Neurological Intensive Care Medicine and Neurorehabilitation

Research output: Contribution to journal › Review article › peer-review

37 Citations (Web of Science)

Original language	English
Pages (from-to)	255-261
Journal	AUTOIMMUNITY REVIEWS
Volume	18
Issue number	3
DOIs	https://doi.org/10.1016/j.autrev.2018.09.012
Publication status	Published - 2019

Keywords

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
DISEASE REACTIVATION
GLATIRAMER ACETATE
DIMETHYL FUMARATE
FINGOLIMOD
RISK
THERAPY
DISCONTINUATION
RECOMMENDATIONS
PREDICTORS

Access to Document

10.1016/j.autrev.2018.09.012

Cite this

@article{d6d90d4a376344358ce59fb80cf0da9a,

title = "A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.",

keywords = "PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, DISEASE REACTIVATION, GLATIRAMER ACETATE, DIMETHYL FUMARATE, FINGOLIMOD, RISK, THERAPY, DISCONTINUATION, RECOMMENDATIONS, PREDICTORS",

author = "Johann Sellner and Rommer, \{Paulus Stefan\}",

note = "Sellner: Paracelsus Med Univ, Dept Neurol, Salzburg, Austria; ",

year = "2019",

doi = "10.1016/j.autrev.2018.09.012",

language = "English",

volume = "18",

pages = "255--261",

journal = "AUTOIMMUNITY REVIEWS",

issn = "1568-9972",

publisher = "Elsevier ",

number = "3",

}

TY - JOUR

T1 - A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.

AU - Sellner, Johann

AU - Rommer, Paulus Stefan

N1 - Sellner: Paracelsus Med Univ, Dept Neurol, Salzburg, Austria;

PY - 2019

Y1 - 2019

KW - PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

KW - DISEASE REACTIVATION

KW - GLATIRAMER ACETATE

KW - DIMETHYL FUMARATE

KW - FINGOLIMOD

KW - RISK

KW - THERAPY

KW - DISCONTINUATION

KW - RECOMMENDATIONS

KW - PREDICTORS

U2 - 10.1016/j.autrev.2018.09.012

DO - 10.1016/j.autrev.2018.09.012

M3 - Review article

C2 - 30639651

SN - 1568-9972

VL - 18

SP - 255

EP - 261

JO - AUTOIMMUNITY REVIEWS

JF - AUTOIMMUNITY REVIEWS

IS - 3

ER -